arrow
M

Mario Giuliano

university of naples federico ii
H指数:45
被引数:7,601

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Drugging the luminal axis end to end: a review of next-generation endocrine and targeted therapies in HR+/HER2- metastatic breast cancer.

靶向管腔轴:HR+/HER2-转移性乳腺癌下一代内分泌和靶向疗法的综述

2026-10-230
OAAI
Ki67 assessment, digital image analysis, and PAM50/Prosigna subtype divergence in early ER-positive breast cancer

Ki67评估、数字图像分析以及PAM50/Prosigna亚型差异在早期ER阳性乳腺癌中的研究

2026-07-310
OA
Strengths and Pitfalls of NNT and NNH in Early Breast Cancer Escalation Trials

早期乳腺癌升级试验中NNT和NNH的优缺点

2026-05-290
OAAI
HER2-low breast cancer is immune-cold: insights into tumor-infiltrating immune cells and implications for immunotherapy

HER2-low乳腺癌是免疫冷型肿瘤:肿瘤浸润免疫细胞的见解及其对免疫治疗的启示

2025-12-030
OAAI
Adipocyte-derived extracellular vesicles sustain mitochondrial metabolism in breast cancer cells: New insights into the cross-talk between cancer cells and the tumor microenvironment

脂肪细胞来源的细胞外囊泡维持乳腺癌细胞线粒体代谢:对癌细胞与肿瘤微环境之间相互作用的新见解

2025-12-011
PRE
Association of Neoadjuvant Chemotherapy Dose Intensity with Pathological Complete Response and Event-Free Survival in HER2-Negative Early Breast Cancer

新辅助化疗剂量强度与HER2阴性早期乳腺癌病理完全缓解及无事件生存期的关系

2025-11-120
PRE
RSC4All as a machine learning nomogram to predict RSClin™ results in HR+/HER2- node-negative early breast cancer

RSC4All 作为一种机器学习列线图,用于预测 HR+/HER2- 淋巴结阴性早期乳腺癌的 RSClin™ 结果

2025-10-070
OAAI
Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysis

真实世界研究与随机研究之间帕博西利布联合内分泌疗法在激素受体阳性/人表皮生长因子受体2阴性转移性乳腺癌中的比较疗效:系统评价与meta分析

2025-10-010
OAAI
Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: a systematic review and network meta-analysis

HR+/HER2−转移性乳腺癌患者在CDK4/6抑制剂进展后接受全身治疗的疗效与安全性:一项系统评价和网络荟萃分析

2025-09-300
OAAI
Trastuzumab plus lapatinib or chemotherapy in patients with HER2-overexpressed advanced breast cancer: a randomized, phase II trial (GIM12-TYPHER)

曲妥珠单抗联合拉帕替尼或化疗在HER2过表达的晚期乳腺癌患者中的应用:一项随机、II期试验(GIM12-TYPHER)

2025-07-010
OAAI
Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid D letrozole in premenopausal hormone receptor-positive early breast cancer patients
2025-01-010
PRE
Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type

根据BRCA结构域突变和突变类型,PARP抑制剂在晚期高级别浆液性卵巢癌中的疗效

2024-09-093
OAAI
The complex relationship between circulating tumor cells (CTCs) and brain metastases (BMs) in metastatic breast cancer (mBC): A retrospective pooled analysis

转移性乳腺癌(mBC)中循环肿瘤细胞(CTCs)与脑转移(BMs)之间的复杂关系:一项回顾性合并分析

2024-09-010
PRE